Skip to content

Exposures Provider ICEES and ICEES KG Terms and Conditions of Use

karafecho edited this page Sep 28, 2022 · 1 revision

ICEES+ and ICEES KG Terms and Conditions of Use

General Terms and Conditions of Service

The Translator Integrated Clinical and Environmental Exposures Service (ICEES) is providing you with Data that have been de-identified in accordance with 45 C.F.R. §§ 164.514(a) and (b) of HIPAA and that UNC Health is permitted to provide under 45 C.F.R. § 164.502(d)(2). Recipient agrees to notify UNC Health via the Renaissance Computing Institute at UNC Chapel Hill in the event that Recipient receives any identifiable data in error and to take such measures to return the identifiable data and/or destroy it at the direction of UNC Health.

ICEES is accessible through two general services: (1) ICEES+ is fully featured and supports functionalities such as dynamic cohort creation and exploratory bivariate and multivariate analysis; and (2) ICEES KG is static and supports knowledge graph queries over a pre-computed correlational matrix. Both ICEES+ and ICEES KG support use cases on asthma and related common pulmonary disorders, primary ciliary dyskinesia and related rare pulmonary disorders, coronavirus infection (COVID), and drug-induced liver injury (DILI), with additional use cases planned.

Restrictions on Recipient’s Use of Data

Recipient further agrees to use the Data exclusively for the purposes and functionalities provided by the ICEES service: cohort discovery; feature-rich cohort discovery; hypothesis-driven queries; and exploratory queries. Recipient agrees to use appropriate safeguards to protect the Data from misuse and unauthorized access or disclosure. Recipient will report to UNC Health any unauthorized access, use, or disclosure of the Data not provided for by the Service of which Recipient becomes aware. Recipient will not attempt to identify the individuals whose information is contained in any Data transferred pursuant to this Service Agreement or attempt to contact those individuals. Recipient agrees not to sell the Data to any third party for any purpose. Recipient agrees not to disclose or publish the Data in any manner that would identify the Data as originating from UNC Health. Finally, Recipient agrees to reasonably limit the number of queries to the Service per IP address within a given time interval, in order to prevent rapid ‘attacks’ on the Service.

Attribution and Secondary Products

We require that users of this service provide proper attribution for any secondary products (e.g., manuscripts, podium presentations, software) derived from the use of ICEES. Attribution must include acknowledgement or, if appropriate, co-authorship of any individual person(s) who contributed significantly to secondary products resulting from use of this service. Attribution must further include acknowledgement of support from the National Center for Advancing Translational Sciences, National Institutes of Health [OT3TR002020, OT2TR003430, UL1TR002489, UL1TR002489-03S4] [ICEES asthma, ICEES COVID, ICEES DILI, and ICEES PCD datasets], the Clinical Research Branch, Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health [ZID ES103354-01] [ICEES asthma dataset, ICEES COVID dataset], and the National Institute of Diabetes and Digestive and Kidney Diseases [5U01DK065201] [ICEES DILI dataset]. Please also acknowledge the Renaissance Computing Institute, the North Carolina Translational and Clinical Sciences Institute, the Clinical Research Branch of the National Institute of Environmental Health Sciences [ICEES asthma dataset, ICEES COVID dataset], the Drug Induced Liver Injury Network [ICEES DILI dataset], and any affiliated team members who contributed to the work. All publications and secondary products must first be submitted to the Translator Publications Committee (and also to the DILI Network Publications Committee for publications and secondary products derived from the ICEES DILI dataset) for review and approval before they are finalized and released for public consumption.

For additional information such as the process for submitting secondary products for committee review, or to report issues, please contact Karamarie Fecho.

Clone this wiki locally